Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer

• Treatment with epigenomic controller, OTX-2002, resulted in robust in vivo efficacy in xenograft tumor models
• OTX-2002 successfully achieved pre-transcriptional downregulation of hepatocyte MYC gene expression in non-human primates
• Clinical potential of OTX-2002 as a monotherapy or in combination with existing standard-of-care therapies, including immune checkpoint inhibitors
• IND filed by the company to advance OTX-2002 into the clinic

Excerpt from the Press Release:

CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, announces the presentation of new preclinical data on its lead product candidate, OTX-2002, to regulate expression of the c-Myc (MYC) oncogene through epigenetic modulation in multiple models of hepatocellular carcinoma (HCC) in a poster presentation at the European Society of Medical Oncology (ESMO) 2022 World Congress on Gastrointestinal (GI) Cancer, taking place in Barcelona, Spain, June 29 – July 2, 2022.

“We are proud to present these new data and add to the wealth of evidence supporting the potential of OTX-2002 as a new treatment option for patients suffering from HCC,” said Thomas McCauley, Ph.D., Omega’s Chief Scientific Officer. “In addition to providing strong evidence of OTX-2002’s activity in the most translationally relevant species to human, non-human primates, the data support its potential as a monotherapy as well as its ability to synergize with existing treatment options. We believe epigenomic programming offers a promising avenue to precisely target previously undruggable genes, like MYC, that overcomes the compensatory mechanisms that have hindered previous modalities. We have recently filed an IND with the FDA for OTX-2002 and look forward to continuing to advance towards the clinic in service of patients.”Key findings:

• In non-human primates, treatment with OTX-2002 resulted in durable reduction of MYC mRNA levels in liver consistent with previous in vitro and in vivo studies
• OTX-2002 treatment decreased MYC mRNA and protein levels and cell viability in multiple HCC cell lines, while sparing normal cells
• OTX-2002 significantly reduced tumor growth in HCC xenografts models

Click the button below to read the entire Press Release:

Continue Reading The Press Release